| HOME >> MEDICINE >> TECHNOLOGY |
rash, some of which were severe, accompanied by myalgia, fever,
erythema, desquamation, and mucosal erosions were reported.
Discontinue and initiate appropriate treatment if severe skin rash
develops.
-- APTIVUS should be used with caution in patients with a known
sulfonamide allergy.
-- New onset diabetes mellitus, exacerbation of pre-existing diabetes
mellitus, hyperglycemia and increased bleeding (in patients with
hemophilia) have been reported in patients taking protease inhibitors.
A causal relationship between protease inhibitors and these events has
not been established.
-- Immune reconstitution syndrome has been reported in patients treated
with combination antiretroviral therapy, including APTIVUS/r.
-- Redistribution and/or accumulation of body fat have been observed in
patients receiving antiretroviral therapy. A causal relationship has
not been established.
-- Treatment with APTIVUS/r has resulted in large increases in total
cholesterol and triglycerides, which should be monitored prior to and
during APTIVUS/r therapy.
-- Because the potential for HIV cross-resistance among protease
inhibitors has not been fully explored in APTIVUS/r-treated patients,
it is unknown what effect therapy with APTIVUS will have on the
activity of subsequently administered protease inhibitors.
-- APTIVUS must be co-administered with 200 mg of ritonavir to exert its
therapeutic effect. Failure to correctly co-administer APTIVUS with
ritonavir will result in reduced plasma levels of tipranavir that will
be insufficient to achieve the desired antiviral effect and will alter
some drug interactions.
-- Please refer to the complete ritonavir prescribing information for a
description of ritonavir contraindications and
'/>"/>
| SOURCE Boehringer Ingelheim Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |